A novel <i>KIF5B‐ALK</i> variant in nonsmall cell lung cancer

Wong, Daisy Wing-Sze; Leung, Elaine Lai‐Han; Wong, Sunny Kit-Man; Tin, Vicky Pui‐Chi; Sihoe, Alan Dart-Loon; Cheng, Lin; Au, Joseph Siu-Kie; Chung, Lap-Ping; Wong, Maria Pik

doi:10.1002/cncr.25843

Cited by 86 publications

(60 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in addition to EML4, the TRK-fused gene (TFG; refs. [4][5][6] and the kinesin family member 5B (KIF5B; refs. 4-6) have been described to be fused to ALK in rare cases (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Massarelli

Papadimitrakopoulou

2015

Clinical Cancer Research

View full text Add to dashboard Cite

Over the past decade, the non-small cell lung cancer therapeutics landscape has been dominated by the increasing focus on identification and validation of molecular targets, as well as the identification of the best candidate agents to address these targets. Among the notable successes have been the approval of erlotinib, gefitinib, and afatinib for the EGFR mutation, and more recently crizotinib for anaplastic lymphoma kinase (ALK) gene rearrangement. Despite the excellent efficacy of crizotinib, several mechanisms of resistance, including secondary mutation in the ALK gene, eventually result in disease progression, and several second-generation ALK inhibitors, notably ceritinib, have demonstrated evidence of clinical activity in this setting. This review discusses the data associated with the recent accelerated approval of ceritinib for treatment of patients with ALK-positive, metastatic lung adenocarcinoma with disease progression on or who are intolerant to crizotinib.

show abstract

Section: Introductionmentioning

confidence: 99%

Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Massarelli

Papadimitrakopoulou

2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Finally, two different variants involving the KIF5B and ALK genes have been described in a small subset of NSCLC (Takeuchi et al 2009, Wong et al 2011.…”

Section: Alk In Epithelial Cancersmentioning

confidence: 99%

Anaplastic lymphoma kinase in human cancer

Barreca

Lasorsa

Riera

et al. 2011

Journal of Molecular Endocrinology

117

View full text Add to dashboard Cite

The receptor tyrosine kinases (RTKs) play a critical role, controlling cell proliferation, survival, and differentiation of normal cells. Their pivotal function has been firmly established in the pathogenesis of many cancers as well. The anaplastic lymphoma kinase (ALK), a transmembrane RTK, originally identified in the nucleophosmin (NPM)-ALK chimera of anaplastic large cell lymphoma, has emerged as a novel tumorigenic player in several human cancers. In this review, we describe the expression of the ALK-RTK, its related fusion proteins, and their molecular mechanisms of activation. Novel tailored strategies are briefly illustrated for the treatment of ALK-positive neoplasms.

show abstract

“…However, thirteen variants of EML4-ALK have been already described according to the break point on EML4 (from exon 2 to exon 20) [3]. Furthermore, beside EML4, TFG [1] and KIF5B [6,7] have also been described to be fused to ALK in rare cases. Thus, RT-PCR has to be multiplexed, i.e.…”

Section: Introductionmentioning

confidence: 96%

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers

et al. 2012

View full text Add to dashboard Cite

A novel KIF5B‐ALK variant in nonsmall cell lung cancer

Abstract: The discovery of the novel KIF5B-ALK variant further consolidated the role of aberrant ALK signaling in lung carcinogenesis.

Cited by 86 publications

References 30 publications

Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

Anaplastic lymphoma kinase in human cancer

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers

Contact Info

Product

Resources

About